{"id":55716,"date":"2022-09-27T09:21:55","date_gmt":"2022-09-26T23:51:55","guid":{"rendered":"https:\/\/www.aumanufacturing.com.au\/?p=55716"},"modified":"2022-09-27T09:24:53","modified_gmt":"2022-09-26T23:54:53","slug":"pfizer-acquires-uq-spinout-for-179-million","status":"publish","type":"post","link":"https:\/\/www.aumanufacturing.com.au\/pfizer-acquires-uq-spinout-for-179-million","title":{"rendered":"Pfizer acquires UQ spinout for $179 million"},"content":{"rendered":"
Pharmaceutical giant Pfizer finalised the acquisition of Brisbane digital health startup ResApp Health for $179 million on Monday.<\/span><\/p>\n ResApp uses technology licensed from University of Queensland commercialisation company UniQuest in 2014, and developed by a team led by Associate Professor Udantha <\/span>Abeyratne<\/span><\/a>. It interprets a patient\u2019s cough through a smartphone app to diagnose respiratory diseases including asthma, pneumonia, bronchiolitis and croup.<\/span><\/p>\n \u201cThis is one of the most exciting Australian biotech deals to come out of university research,\u201d said UniQuest CEO Dr Dean Moss in a statement.<\/span><\/p>